News
The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of ...
The FDA has approved a supplemental biologics application for Leqembi Iqlik subcutaneous injection for maintenance dosing in ...
While the approval of Leqembi Iqlik bodes well for Biogen and Eisai’s planned application for a subcutaneous induction ...
After 18 months of intravenous administration of lecanemab (Leqembi), patients may now transition to subcutaneous delivery using the Leqembi Iqlik autoinjector.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback